申请人:Pfizer Inc.
公开号:US04914101A1
公开(公告)日:1990-04-03
##STR1## and pharmaceutically acceptable salts thereof, wherein R.sup.1 is hydrogen, halogen or C.sub.1 to C.sub.4 alkyl; R.sup.2 is hydrogen or C.sub.1 to C.sub.4 alkyl; and Ar is phenyl or phenyl substituted with one or more substituents selected from C.sub.1 to C.sub.4 alkyl, halo, trifluoromethyl, nitro, hydroxyl, halophenyl, or C.sub.1 to C.sub.4 alkoxy. The compounds are useful in treating inflammation or other prostaglandin or leukotriene mediated diseases.
该化合物及其药学上可接受的盐,其中R.sup.1是氢,卤素或C.sub.1到C.sub.4烷基;R.sup.2是氢或C.sub.1到C.sub.4烷基;Ar是苯或苯取代物,所述苯取代物选自C.sub.1到C.sub.4烷基,卤素,三氟甲基,硝基,羟基,卤苯基或C.sub.1到C.sub.4烷氧基。该化合物对治疗炎症或其他前列腺素或白三烯介导的疾病有用。